Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

Welcome to ITP Sanofi Campus

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

You are about to leave the T1D website

Welcome to the T1D Sanofi Website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

astma

Astma

There’s more to uncontrolled asthma
<h3>DUPIXENT goes beyond addressing EOS by impacting type 2 inflammation1-3</h3>

<a href="https://pro.campus.sanofi/nl/astma/artikelen/dupixent-asthma#patient-types">550 mL improvement in lung function5,c</a> (single-arm, open label extension study)

<a href="https://pro.campus.sanofi/nl/astma/artikelen/dupixent-asthma#patient-types">75% reduction in annualized severe exacerbations5,d</a> (single-arm, open label extension study)

<a href="https://pro.campus.sanofi/nl/astma/artikelen/dupixent-asthma#patient-types">86% of patients reduced or eliminated OCS6,e</a> (68% with placebo, P&lt;0.001)

a&nbsp;Systemic eosinophilic and allergic inflammation and local airway inflammation. b&nbsp;Improvement in FEV1 at Week 2 (primary endpoint was Week 12); sustained through Week 52 (QUEST) and ~3 years (TRAVERSE OLE); exacerbation reduction through Week 52 (QUEST); reduced FeNO, mucus plugging, and airway resistance and increased airway volume at Week 24 (VESTIGE). c&nbsp;550 mL improvement in FEV1 at Week 52 with DUPIXENT 200/300 mg + SOC (n=69) in patients with EOS ≥300, FeNO ≥25, and allergic asthma on high-dose ICS. Only descriptive statistics (no P-values) are available for data due to the single-arm nature of the open-label extension study. d&nbsp;75% reduction in annualized severe exacerbations at Week 52 with DUPIXENT 200/300 mg + SOC (n=91) in patients with EOS ≥300, FeNO ≥25, and allergic asthma on high-dose ICS. Only descriptive statistics (no P-values) are available for data due to the single-arm nature of the open-label extension study. 
 e 86% of patients reduced or eliminated OCS use by Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (P&lt;0.001). f&nbsp;Prebronchodilator FEV1, P nominal &lt;0,001

<h2>INDICATIONS1</h2>
DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
DUPIXENT is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
See other indications in the compulsory information.

SPECIALTY-CARE

DUPIXENT

ASTHMA

RESPIRATORY

Price and reimbursement information: U.R. Financing is done via add-on. For prices, see the Z-index tax.

<h2 id="moa">MOD/MOA</h2>
<h3>MOD</h3>
IL-4 AND IL-13 ARE KEY AND CENTRAL DRIVERS OF TYPE 2 INFLAMMATION2,11

IL-4 and IL-13 contribute to systemic eosinophilic and allergic inflammation and local inflammatory effects2,11

<h3 id="moaspecific">MOA</h3>
MORE PRECISION TO TARGET BOTH IL-4 AND IL-13 TO IMPACT TYPE 2 INFLAMMATION AT THE SOURCE1,3

DUPIXENT GOES BEYOND ADDRESSING EOS BY PRECISELY TARGETING IL-4 AND IL-13 TO PROTECT AGAINST STRUCTURAL AIRWAY DAMAGE AND DISEASE PROGRESSION1-3

a&nbsp;Systemic eosinophilic and allergic inflammation and local airway inflammation.

<h2 id="patienttypes">Patient Types</h2>
MORE POSSIBILITIES FOR PATIENTS WITH TYPE 2 ASTHMA1

Type 2 Asthma (12+ Years)

Type 2 Asthma With OCS Use (12+ Years)

Type 2 Asthma With Allergic Status (12+ Years)

Type 2 Asthma in Children (6-11 Years)

Patient profiles are representative and are not actual patients. Individual results may vary.

Type 2 Asthma (12+)

Type 2 Asthma With OCS Use (12+)

Type 2 Asthma With Allergic Phenotype (12+)

Type 2 Asthma in Children (6-11)

440 mL improvement5,a (single-arm, open-label extension study)

530 mL improvement5,b (single-arm, open-label extension study)

440 mL improvement5,c (single-arm, open-label extension study)

500 mL improvement5,d (single-arm, open-label extension study)

SOME PATIENTS GAINED MORE THAN A HALF-LITER IMPROVEMENT IN LUNG FUNCTION5

a&nbsp;440 mL improvement in pre-BD FEV1 from baseline at Year 3 with DUPIXENT 300 mg Q2W (n=51) in patients with EOS ≥300 and allergic asthma on high-dose ICS. b&nbsp;530 mL improvement in pre-BD FEV1 from baseline at Year 3 with DUPIXENT 300 mg Q2W (n=70) in patients with EOS ≥300 and FeNO ≥25 on high-dose ICS. c&nbsp;440 mL improvement in pre-BD FEV1 from baseline at Year 3 with DUPIXENT 300 mg Q2W (n=57) in patients with FeNO ≥25 and allergic asthma on high-dose ICS. d&nbsp;500 mL improvement in pre-BD FEV1 from baseline at Year 3 with DUPIXENT 300 mg Q2W (n=34) in patients with EOS ≥300, FeNO ≥25 and allergic asthma on high-dose ICS. a-d&nbsp;Single-arm, open-label extension study - descriptive statistics available (no p-value).

<h3>Elevated FeNO</h3>
BETTER BREATHING MEANS MORE POSSIBILITIES FOR TYPE 2 ASTHMA PATIENTS WITH ELEVATED FeNO18,22

~3 YEARS OF SUSTAINED RELIEF was seen in the OLE study18,c

PER GINA, ELEVATED FeNO IS STRONGLY PREDICTIVE OF TREATMENT RESPONSE WITH DUPIXENT23

a&nbsp;Primary endpoint was Week 12. b&nbsp;LSM difference, 360 mL (95% CI: 230, 480 mL). c&nbsp;As observed across a 52-week trial (QUEST) and a 96-week, open-label extension trial (TRAVERSE) of adult and adolescent patients.

<h3>Elevated EOS</h3>
BETTER BREATHING MEANS MORE POSSIBILITIES FOR PATIENTS WITH ELEVATED EOS22

PER GINA, ELEVATED EOS IS STRONGLY PREDICTIVE OF TREATMENT RESPONSE WITH DUPIXENT23

a&nbsp;Primary endpoint was Week 12. b&nbsp;LSM difference, 300 mL (95% CI: 180, 410 mL). c&nbsp;As observed across a 52-week trial (QUEST) and a 96-week, open-label extension trial (TRAVERSE) of adult and adolescent patients.

EOS ≥500 cells/μL

a&nbsp;59% reduction in annualized severe exacerbations at Week 52 with DUPIXENT 200/300 mg + SOC (n=141) vs placebo + SOC (n=93) (0.270 vs 0.612) (P&lt;0.0001) in patients with EOS ≥300 and allergic asthma on high-dose ICS. b&nbsp;73% reduction in annualized severe exacerbations at Week 52 with DUPIXENT 200/300 mg + SOC (n=180) vs placebo + SOC (n=104) (0.189 vs 0.396) (P&lt;0.0001) in patients with EOS ≥300 and FeNO ≥25 on high-dose ICS. c&nbsp;64% reduction in annualized severe exacerbations at Week 52 with DUPIXENT 200/300 mg + SOC (n=165) vs placebo + SOC (n=99) and (0.241 vs 0.534) (P&lt;0.0001) in patients with FeNO ≥25 and allergic asthma on high-dose ICS. d&nbsp;75% reduction in annualized severe exacerbations at Week 52 with DUPIXENT 200/300 mg + SOC (n=91) vs placebo + SOC (n=64) (0.152 vs 0.412) (P&lt;0.0001) in patients with EOS ≥300, FeNO ≥25, and allergic asthma on high-dose ICS.

~3 YEARS OF SUSTAINED PROTECTION was seen in the OLE study18,b

a&nbsp;In annualized severe exacerbations at Week 52 (QUEST) with DUPIXENT 200 mg + SOC (n=145) vs placebo + SOC (n=78) (0.40 vs 1.30) (P&lt;0.001), and 55% reduction with DUPIXENT 300 mg + SOC (n=159) vs placebo + SOC (n=89) (0.57 vs 1.26) (P&lt;0.001). b&nbsp;As observed across a 52-week trial (QUEST) and a 96-week, open-label extension trial (TRAVERSE) of adult and adolescent patients.
A severe exacerbation event was defined as a deterioration of asthma requiring the use of systemic corticosteroids for ≥3 days or hospitalization or an ED visit. The population in dupilumab asthma trials included patients on medium- to high-dose ICS. All data presented above represent the high-dose ICS population.

~3 YEARS OF SUSTAINED PROTECTION was seen in the OLE study18,d

a&nbsp;In annualized severe exacerbations at Week 52 with DUPIXENT 200 mg + SOC (n=223) vs placebo + SOC (n=126) (0.56 vs 1.24) (P&lt;0.001), and up to 53% reduction with DUPIXENT 300 mg + SOC (n=228) vs placebo + SOC (n=127) (0.53 vs 1.15) (P&lt;0.001). b&nbsp;In annualized severe exacerbations at Week 52 with DUPIXENT 300 mg + SOC (n=144) vs placebo + SOC (n=79) (0.51 vs 1.48) (P&lt;0.001), and up to 59% reduction with DUPIXENT 200 mg + SOC (n=128) vs placebo + SOC (n=80) (0.55 vs 1.35) (P&lt;0.001). c&nbsp;As observed across a 52-week trial (QUEST) and a 96-week, open-label extension trial (TRAVERSE) of adult and adolescent patients. Only statistic available (no p-value). d&nbsp;As observed across a 52-week trial (QUEST) and a 96-week, open-label extension trial (TRAVERSE) of adult and adolescent patients. Only statistic available (no p-value).
A severe exacerbation event was defined as a deterioration of asthma requiring the use of systemic corticosteroids for ≥3 days or hospitalization or an ED visit.
The population in dupilumab asthma trials included patients on medium- to high-dose ICS. All data presented above represent the high-dose ICS population.

STUDY DESIGN

<h3>OCS Elimination (24 weeks, 49-58 weeks)</h3>
<h3>24 weeks</h3>
DUPIXENT DOES MORE TO ELIMINATE OCS24

a&nbsp;86% of patients reduced or eliminated OCS use by Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (P&lt;0.001). b&nbsp;220 mL improvement in pre-bronchodilator FEV1 at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference, 220 mL [95% CI: 90, 340 mL]). c&nbsp;59% reduction in annualized rate of severe exacerbations at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]).

<h3>49-58 weeks</h3>
DUPIXENT DOES MORE TO ENSURE PATIENTS REMAIN OCS FREE19

a At Week 24 of VENTURE, 48 of 90 in the DUPIXENT/DUPIXENT patient group (53.3%) and 29 of 97 in the placebo/DUPIXENT patient group (29.9%) were free of OCS treatment. Of these, 31 of 33 in the DUPIXENT/DUPIXENT patient group and 21 of 21 in the placebo/DUPIXENT patient group with available OCS dose data remained free of OCS treatment at TRAVERSE Week 48. 14 of 14 in the DUPIXENT/DUPIXENT patient group and 9 of 9 in the placebo/DUPIXENT patient group continued to be free of OCS treatment at TRAVERSE Week 96. b 250 mL improvement in FEV1 at Week 96 of TRAVERSE from VENTURE baseline in the DUPIXENT/DUPIXENT patient group (n=28) vs 360 mL in the placebo/DUPIXENT patient group (n=32). c Of the 67 DUPIXENT/DUPIXENT patients who were treated up to 96 weeks in TRAVERSE, 90% were exacerbation-free during Weeks 48 through 96 of TRAVERSE.

<h3 id="mucusplugs">Mucus Plugs</h3>
DUPIXENT AND MUCUS PLUGS4,6

a&nbsp;In the high-dose ICS population, 3.8 decrease in global mucus score at Week 24 from baseline score of 8.3 with DUPIXENT 300 mg + SOC (n=34) vs 1.5 increase from baseline score of 6.9 with placebo + SOC (n=21) (LSM difference: -5.3 [95% CI: - 7.704, -2.821], nominal P&lt;0.0001). b&nbsp;Mucus scores range from 0 to 20, with higher scores indicating airway occlusion. Scores between 0.5 to 3.5 indicate low mucus levels, and scores between 4 and 20 indicate high mucus levels.26 c&nbsp;Pearson’s correlation coefficient for mucus score/pre-BD FEV1: r[60]=-0.61, nominal P&lt;0.001. d&nbsp;LS mean change in ACQ-7 score from baseline at Week 24: -1.4 from 2.9 at baseline with DUPIXENT + SOC (n=72) vs -0.6 from 3.0 at baseline with placebo + SOC (n=37) (LSM difference vs placebo: -0.7 [95% CI: -1.1, -0.4]; nominal P&lt;0.001).

STUDY DESIGN4

89,6% achieves ≥ 0.5 improvement in ACQ-55

a Achieved the minimal MCID (ACQ-5 improvement ≥0.5) in the dupilumab/dupilumab treatment arm of the TRAVERSE open-label extension study (~3 years of treatment with dupilumab).

<h3>Study Designs (adolescents/adults, children)</h3>
<h3>adolescents/adults</h3>
DUPIXENT WAS STUDIED IN A CLINICAL PROGRAM THAT ENROLLED ~3,000 PATIENTS1,22,24,28
Clinical trials included patients (12+) with uncontrolled, moderate-to-severe asthma driven by type 2 inflammation1,22,24,28

a&nbsp;With 400 mg loading dose. b&nbsp;With 600 mg loading dose. c&nbsp;OCS-dependent patients required daily oral corticosteroids, in addition to regular use of high-dose–inhaled corticosteroids plus an additional controller. d&nbsp;OCS dose was reduced every 4 weeks during the OCS reduction phase (Weeks 4-20), as long as asthma control was maintained.

PATIENT CHARACTERISTICS

TRAVERSE OLE STUDY19

VESTIGE

SEE INDICATIONS

<h2 id="safety">Safety</h2>
<h3>Safety</h3>
~6 YEARS OF ESTABLISHED SAFETY IN ASTHMA1
DUPIXENT was consistently well-tolerated across adult and adolescent asthma patients, exhibiting a safety profile similar to that observed in pediatric populations1,a

a&nbsp;As observed across 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks duration (DRI12544, QUEST, and VENTURE), and a 96-week, open-label extension trial (TRAVERSE) and another 3-year open-label extension study (TRAVERSE CONTINUATION), in adult and adolescent patients. The safety profile observed in the pediatric asthma clinical study (a 52-week multicenter, randomized, double-blind, placebo-controlled study [VOYAGE]) was similar to that seen in adults. b&nbsp;Common (≥1/100 to &lt;1/10); Uncommon (≥1/1,000 to &lt;1/100); Rare (≥1/10,000 to &lt;1/1,000). c&nbsp;From postmarketing reporting. d&nbsp;Eye disorders and oral herpes occurred predominantly in atopic dermatitis studies. The frequencies for eye pruritus, blepharitis, and dry eye were common, and ulcerative keratitis was uncommon in atopic dermatitis studies. In adults with moderate-to-severe atopic dermatitis, the safety and tolerability profile of DUPIXENT has been studied for 4 years in an open-label extension study and was demonstrated to be generally consistent with the 52-week data.
<h3>API</h3>
ABBREVIATED PRESCRIBING INFORMATION

Dupixent® Asthma

Sluit aan bij onze lunchsessies tijdens de ERS 2025.

CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-(COPD)

<h3>Ben jij sneller dan je collega’s?</h3>
Doe mee aan een spannende escape room in a box ‘Breathe or Break’ ervaring! Scherp je kennis aan en los respiratoire puzzels op in een leuke en interactieve omgeving. Kom in contact met je collega’s en vergroot je expertise in deze unieke uitdaging!

<h3>Onder het genot van een broodje winnen van je collega’s?</h3>
Het kan tijdens de grote ERS-Quiz. Streng doch rechtvaardig zal onze quizmaster jullie kennis op het snijvlak van wetenschap, praktijk en algemene ontwikkeling testen.

<h2>Meet the Expert: De toekomst van COPD</h2>

<h3>Wil jij bijgepraat worden over de nieuwste ontwikkelingen op het gebied van COPD?</h3>
Tijdens deze exclusieve sessie neemt een toonaangevende expert je mee in de rol van type 2-inflammatie in COPD, evenals de ontwikkeling rondom biologicals. Grijp je kans om je vragen te stellen, je kennis te verdiepen en te netwerken met collega’s!

Locatie: 
 nhow Amsterdam Rai hotel 
 Europaboulevard 2b, Amsterdam

Elke sessie heeft slechts 25 plaatsen, meld u snel aan. Alle aangeboden gastvrijheid is conform CGR-richtlijnen.

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

Breath Breaks: ERS Lunchsessies 2025

Bij type 2-inflammatie spelen verschillende cytokines een rol en het aantal biologicals dat die cytokines kan remmen, groeit. Welke cytokines spelen welke rol? En welke biological remt welke cytokine? Deze expertvideo maakt het in 4 minuten inzichtelijk.
Het bucket-model is een schematische weergave van type 2-inflammatie, waarin de rol van de alarmines (TSLP en IL-33), effectorcytokines (IL-5, IL-4, IL-13) en de bijbehorende biomarkers eenvoudig wordt laten zien. Professor Lipworth maakt zo de complexe immunologie begrijpelijk en geeft praktische handvatten. Deze kennis biedt mogelijk ondersteuning bij het kiezen van de passende biological voor uw ernstig type-2 astmapatiënt.

Professor Lipworth geeft snel inzicht met het bucket-model.

Expertvideo: Complexe type 2-inflammatie, verfrissend eenvoudig

Professor Brian Lipworth is het hoofd van het Scottish Centre for Respiratory Research van de University of Dundee. Zijn onderzoeksgroep is in 1991 opgericht en heeft een internationale reputatie op het gebied van klinisch onderzoek naar de luchtwegen. De combinatie van zijn toonaangevende expertise in onderzoek én in de kliniek geeft unieke inzichten wat betreft de behandeling van astma en COPD en de rol van biologicals daarbij.1

Referenties

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

In de videoserie Astma Alert vat onze collega Sarah Slager recente wetenschappelijke ontwikkelingen op het gebied van ernstig astma in een ademteug samen. In elke aflevering staat een nieuwe publicatie of ontwikkeling centraal. Op deze manier blijft u gemakkelijk op de hoogte van de laatste wetenschap! Wilt u meer weten over het besproken onderwerp?

<h2>Aflevering 3 - Elke kuur telt: OCS (over)gebruik bij astma (3:46 min)</h2>

<h2>Aflevering 2 - Mucus plugging bij astma: een taai probleem (4:07 min)</h2>

<h2>Aflevering 1 - Astma-remissie met dupilumab: voorspellers van respons (3:48 min)</h2>

Lees de publicatie

Astma Alert

The European Respiratory Society annual congress took place in Amsterdam this year. Whether or not you were able to attend the congress, here is an overview of the highlights of this major European event bringing together the scientific community in respiratory care.
Distinguished international experts delivered outstanding lectures on Asthma and COPD.

<figure class="table" style="width:100%;">
 <table style="background-color:#7a00e6;border-color:#7a00e6;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7a00e6;border-color:#7a00e6;">
 Interview with:
 <h3 style="text-align:center;">Mireille Melles</h3></td>
 </tr>
 </tbody>
 </table>
</figure>

Astma

Voor zorgverleners

Dupixent® Asthma

Patienten hulpmiddelen

Informatiematerialen astma

Events

Breath Breaks: ERS Lunchsessies 2025

Educatie

Expertvideo: Complexe type 2-inflammatie, verfrissend eenvoudig

Astma Alert

Highlights ERS 2025